The following criteria are recommended by RECIST for the evaluation of target lesions in patients with NSCLC1

Complete response (CR)
Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.1

Partial response (PR)
At least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.1

Progressive disease (PD)
At least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum, if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of ≥1 new lesion(s) is also considered progression).1

Stable disease (SD)
Neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study.1

Duration of response, PFS and stable disease
The duration of response, stable disease and PFS clinical endpoints are influenced by the frequency of follow-up after baseline evaluation. It is not within the scope of the RECIST guideline to define a standard follow-up frequency. The frequency should consider parameters including disease types, clinical stages, treatment periodicity and standard practice.1

LEARN ABOUT OR



CR: complete response; NSCLC: non-small-cell lung cancer; OR: objective response; PD: progressive disease; PFS: progression-free survival; PR: partial response; RECIST: Response Evaluation Criteria In Solid Tumors; SD: stable disease.